CD34 and cancer: As demonstrated by our results, JAK2-mutated CD34+ cells have lower levels of apoptosis and this might allow the survival of cancer cells, leading to the acquisition of new mutations that drive clonal evolution and disease progression, thus promoting the transition to the so-called “mutator-phenotype” described for MPNs [2,3].